BACKGROUND AND OBJECTIVES: Hyperglycemia in pregnancy is associated with increased risk of offspring childhood obesity. Treatment reduces macrosomia; however, it is unclear if this effect translates into a reduced risk of childhood obesity. We performed a systematic review and meta-analysis of randomized controlled trials to evaluate the efficacy and safety of intensive glycemic management in pregnancy in preventing childhood obesity. METHODS: We searched MEDLINE, EMBASE, CENTRAL and ClinicalTrials.gov up to February 2016 and conference abstracts from 2010 to 2015. Two reviewers independently identified randomized controlled trials evaluating intensive glycemic management interventions for hyperglycemia in pregnancy and included four of the 383 citations initially identified. Two reviewers independently extracted study data and evaluated internal validity of the studies using the Cochrane Collaboration's Risk of Bias tool. Data were pooled using random-effects models. Statistical heterogeneity was quantified using the I 2 test. The primary outcome was age-and sex-adjusted childhood obesity. Secondary outcomes included childhood weight and waist circumference and maternal hypoglycemia during the trial (safety outcome). RESULTS: The four eligible trials (n = 767 children) similarly used lifestyle and insulin to manage gestational hyperglycemia, but only two measured offspring obesity and waist circumference and could be pooled for these outcomes. We found no association between intensive gestational glucose management and childhood obesity at 7-10 years of age (relative risk 0.89, 95% confidence interval (CI) 0.65 to 1.22; two trials; n = 568 children). Waist circumference also did not differ between treatment and control arms (mean difference, − 2.68 cm; 95% CI, − 8.17 to 2.81 cm; two trials; n = 568 children). CONCLUSIONS: Intensive gestational glycemic management is not associated with reduced childhood obesity in offspring, but randomized data is scarce. Long-term follow-up of trials should be prioritized and comprehensive measures of childhood metabolic risk should be considered as outcomes in future trials.
INTRODUCTION

Childhood obesity
1 is a global public health concern 2 and correlates with important comorbidities such as type 2 diabetes in adolescence and early adulthood. 3, 4 A recent systematic review of cohort studies from 188 developed and developing countries found that the prevalence of obesity in children aged 2-17 years nearly doubled between 1980 and 2013. 5 In North America, 12-17% of children are living with obesity. 6, 7 Accordingly, the prevention of childhood obesity has been a World Health Organization priority since 2012. 2 Gestational diabetes mellitus (GDM), defined as glucose intolerance with onset or first recognition during pregnancy, 8 increases the risk for macrosomia at birth and for obesity, metabolic syndrome and type 2 diabetes in childhood. [9] [10] [11] [12] [13] Two benchmark cohort studies found that maternal hyperglycemia in pregnancy linearly increases the risk for fetal macrosomia, without a clear glucose inflection point. [14] [15] [16] [17] As such, it is widely accepted that women at risk of GDM should target normal glycemia during pregnancy [18] [19] [20] [21] reducing risk of childhood obesity; 22, 23 however, the level of evidence on which these recommendations are based is uncertain. The objectives of this systematic review were to identify, critically appraise and meta-analyze data from prospective randomized trials comparing, in pregnant women, the impact of intensive maternal glycemic management on offspring obesity risk in childhood.
MATERIALS AND METHODS
Using an a priori published protocol (PROSPERO #CRD42016038624), we conducted our systematic review using methodological approaches outlined in the Cochrane Handbook for Systematic Reviews 24 and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria. 25 A panel of interdisciplinary experts (endocrinology, developmental origins of diseases and research methodology) formulated the review question, reviewed the search strategies and review methods, and provided input throughout the review process. Study eligibility Inclusion criteria. We included only randomized controlled trials of pregnant women diagnosed with mild GDM, glucose intolerance or hyperglycemia of pregnancy, according to local definitions and diagnosis criteria. All pharmacological and nonpharmacological interventions were accepted.
Exclusion criteria. We excluded all non-randomized studies, trials lacking an untreated comparator group, and trials including women with pregestational type 2 diabetes and/or studies that did not include a separate analysis on women with gestational diabetes.
Study selection. Our primary research question was: 'in women diagnosed with hyperglycemia in pregnancy, is intensive glycemic management targeting normoglycemia during pregnancy associated with reduced measures of offspring obesity, compared to standard of care?'. We defined intensive glycemic management as initiating glycemic management at a glycemic threshold below accepted GDM diagnostic criteria. We used a two-step process for study selection. First, two reviewers (LG and AD) independently screened the titles and abstracts to determine whether a study met the general inclusion criteria. For those meeting criteria, these reviewers independently examined the full texts. Disagreements were resolved by discussion or by third-party adjudication (BW). Study authors were contacted if data as published were incomplete for the needs of the review. Our primary outcome measure was the incidence of age-and sex-adjusted offspring obesity according to the local reference growth chart, expected to correspond to the World Health Organization's 2007 definition of age-and sex-adjusted body mass index (BMI) ⩾ 95th percentile 26 based on the 2000 Center for Disease Control and Prevention growth chart. 23 Secondary outcomes were offspring waist circumference, BMI z-score, fat mass and weight at longest follow-up. To evaluate the safety and acceptability of this intervention for preventing childhood obesity, we also assessed maternal hypoglycemia during the intervention period and health-related quality of life.
Data extraction and quality assessment Two reviewers (LG and AD) independently extracted data from included trials using a standardized and piloted data extraction form. Extracted data included funding sources, demographics of the enrolled mothers and children (gestational age at randomization, maternal age at randomization, pre-pregnancy BMI, maternal smoking status at randomization; child age at latest follow-up), details of the intervention (targeted glycemia, number of research follow up visits, number of daily capillary glucose tests recommended, intervention prescribed: lifestyle, oral hypoglycemic medications, insulin), and maternal and offspring outcomes as described above. When a trial reported results for more than one time period, only results from the longest follow-up were included. Internal validity of included studies was evaluated using the Cochrane Collaboration's Risk of Bias tool. 27 Data synthesis and analysis We analyzed data using Review Manager (RevMan version 5.3.5, the Cochrane Collaboration). Pooled dichotomous data are presented as risk ratio, and pooled continuous data are expressed as mean difference, with 95% confidence intervals (CIs). Statistical heterogeneity was explored and quantified using the I 2 test. Publication bias was not assessed due to the small number of trials included. After validation against the associated protocols and/or trial registration information, no evidence of selective reporting was found for any of the included trials.
RESULTS
Of 383 citations identified, 4 unique trials (plus 8 companion publications), representing a total of 767 children between 4 and 10 years old (Table 1; Figure 1 ) were included. All were randomized controlled trials published in peer-reviewed journals between 1997 and 2015, and conducted in developed countries: Gestational hyperglycemia and child obesity L Guillemette et al Australia, 23 Canada, 28 Sweden 29 and USA. 16 Two trials 23, 29 enrolled women with at least one risk factor for GDM, whereas the other two 16, 28 did not select their participants based on GDM risk factors. Details of the intervention conducted in each trial are presented in Table 2 . All trials were adjudicated to be at unclear or high risk of bias, mostly due to the unclear effectiveness of blinding and to high attrition rates between the trial initiation and the follow-up of children experienced by all studies (Figure 2 ). Inclusion criteria were slightly different between trials, which might have resulted in variable levels of maternal hyperglycemia (Table 2 ). Mean maternal age was 30.2 ± 5.3 years, and between 28 22 and 90% 23 of participants were of Caucasian descent. In all trials, women in the intervention arm attained glycemic targets. In the sole trial that measured both the treatment and control arms' glycemia at the end of pregnancy, 28 the mean difference in glycemia between groups was minimal (0.21 ± 0.93 mmol l − 1 for fasting glucose, and 0.51 ± 1.65 mmol l − 1 1 h post prandial at 36-38 gestational weeks).
For the primary outcome measure, two trials 22, 30 involving 568 pregnant women (follow-up 8.1 ± 1.1 years later) provided data for the meta-analysis of child obesity (Figure 3.1) . The incidence of obesity was not significantly different between groups (19.9% in 36 *Companion articles represent reports involving the same study population for the same intervention trial, including conference abstracts reporting findings from previous or subsequent full-length publications. Abbreviations: 1 h, glycaemia 1 h into the OGTT; 2 h, glycaemia 2 h into the OGTT; 3 h, glycaemia 3 h into the OGTT; FG, fasting glycaemia; GDM, gestational diabetes mellitus; OGTT: oral glucose tolerance test; PPG, post-prandial glycaemia. a Glycemic criteria at which insulin is added to the glycemic management strategy. the treatment arm vs 22.6% in the standard care arm; risk ratio 0.89, 95% CI 0.65 to 1.22; I 2 0%). In a third trial 23 involving 199 pregnant women (follow-up 4.7 ± 0.3 years later), intensive gestational glycemic management failed to reduce the proportion of children with a BMI ⩾ 85th percentile of the 2000 International Obesity Task Force growth chart. 31, 32 Because BMI ⩾ 85th percentile aligns more closely with a classification of overweight than obesity, 33 we considered it to be clinically different from the previous outcome (BMI ⩾ 95th percentile of the 2000 Center for Disease Control and Prevention growth chart) and thus present it as a sub-group analysis. Among the 767 children (5.8 ± 0.6 years old) with available data, the incidence of BMI ⩾ 85th percentile was 31.9% in the treatment arm vs 35.0% in the standard care arm (risk ratio 0.91, 95% CI 0.74 to 1.12, I 2 4%, Figure 3. 2). For waist circumference, the only secondary outcome reported by more than one study, two trials 22, 30 involving 568 pregnant women (follow-up 8.1 ± 1.1 years later) provided data for metaanalysis. Intensive management of gestational hyperglycemia was not associated with significant changes in mean waist circumference in children (58.4 ± 8.4 cm in treatment arm vs 61.5 ± 8.9 cm in standard care arm; mean difference − 2.68, 95% CI − 8.17 to 2.81 cm, I 2 81%, Figure 4 ). Although trials appeared to be clinically similar, statistical heterogeneity was high, possibly because of the large confidence intervals associated with the measurements.
DISCUSSION
We found no conclusive evidence that intensive management of gestational hyperglycemia reduces childhood obesity. There was also no significant reduction of childhood waist circumference. We identified very few clinical trials of intensive management of gestational hyperglycemia investigating the risk of offspring obesity in childhood, resulting in insufficient data to evaluate other indicators of childhood metabolic health or maternal safety (such as hypoglycemic events). Current practices advocating normalization of glycemia in highrisk pregnant women to reduce the risk of childhood obesity appear to be lacking strong scientific evidence. 15, 34 The four trials included in this systematic review observed a reduced risk for macrosomia among pregnant women with hyperglycemia, concurring with recent systematic reviews that confirmed treatment of hyperglycemia halves the relative risk of macrosomia (95% CI, 0.38-0.57); 8, 35 however, these benefits did not translate into a reduced risk for obesity later in childhood. Indeed, although several trials of glucose management in women in mild GDM reported a reduced risk of macrosomia or large-for-gestationalage infants, 8, 35 few of those trials followed the offspring into childhood to determine whether this lowered risk translated into a lower risk of obesity and other cardiometabolic diseases. Moreover, of the four trials included in the current systematic review, all were at similar risk of bias due to unclear blinding to the intervention group and to attrition between the trial and the follow-up study. Finally, the lack of maternal outcomes reported is troubling considering the current clinical/expert moment towards lowering of current GDM diagnostic threshold to capture low-risk women. Investigators have previously called for more trials of glycemic management among high-risk women without GDM that include appropriate follow-up of offspring into childhood. [9] [10] [11] Our results support these calls and reinforce the need for followup of offspring exposed to therapeutic trials during pregnancy before undergoing costly reforms of clinical care and policies for low-risk women. We add that follow-up should be conducted systematically between 1 and 17 years after birth, efforts should be made to limit loss to follow-up and/or sample sizes should be at least 100 offspring per exposure group, and outcomes should include metabolically relevant measures such as waist circumference and fat mass as well as maternal safety and quality of life outcomes.
The strengths of this review include the extensive search strategy used, the multiple databases and trial registries searched, and the hand-search of citations in selected conference proceedings. The included trials were clinically homogenous in their populations, interventions and potential biases. Finally, we used a protocol published a priori and complied with established methodological guidelines in the conduct and reporting of this review. Limitations include pooling data identified at high risk of bias due to attrition, the limited number of included studies, and the lack of representativeness towards developing countries with possibly different healthcare systems.
CONCLUSION
Currently, there is insufficient evidence to support intensive glycemic management of gestational hyperglycemia below current GDM diagnostic threshold to prevent childhood obesity in the offspring. Longitudinal follow-up of children involved in therapeutic trials of mild GDM and GDM are required. To determine whether intensive maternal glycemic management improves metabolic health into childhood, other markers of metabolic risk (for example, fat mass and dyslipidemia) should also be included as outcomes in future clinical trials; moreover, to determine the acceptability of this intervention for childhood obesity, maternal outcomes (for example, hypoglycemia and quality of life) need to be evaluated and reported.
